Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|January 11, 2016
Shire to Buy Baxalta for $32 Billion
January 11, 2016.
Advertisement
Shire announced today that it has entered into an agreement to acquire Baxalta under a cash and stock deal valued at $45.57 per share, or approximately $32 billion.
The combination of Baxalta and Shire would reportedly create "the number-one rare diseases platform in revenue and pipeline depth", with best-in-class products in each of the following franchises: hematology, immunology, neuroscience, lysosomal storage diseases, gastrointestinal/endocrine, and hereditary angioedema (HAE).
Shire CEO Flemming Ornskov said that the expanded portfolio "will drive our growth to over $20 billion in anticipated annual revenues by 2020."
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5